209 related articles for article (PubMed ID: 34160752)
1. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.
Luo Y; Cheng Y; Wu C; Ye H; Chen N; Zhang F; Wei H; Xu B
Invest New Drugs; 2023 Jun; 41(3):503-511. PubMed ID: 37171721
[TBL] [Abstract][Full Text] [Related]
3. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
[TBL] [Abstract][Full Text] [Related]
4. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
[TBL] [Abstract][Full Text] [Related]
6. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Dhawan MS; Bartelink IH; Aggarwal RR; Leng J; Zhang JZ; Pawlowska N; Terranova-Barberio M; Grabowsky JA; Gewitz A; Chien AJ; Moasser M; Kelley RK; Maktabi T; Thomas S; Munster PN
Clin Cancer Res; 2017 Nov; 23(21):6400-6410. PubMed ID: 28790114
[No Abstract] [Full Text] [Related]
7. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
Elmeliegy M; Yu Y; Litton JK; Czibere A; Wilson GG; Tudor IC; Zheng J; Wang DD
J Clin Pharmacol; 2020 Oct; 60(10):1334-1343. PubMed ID: 32468645
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
Yu Y; Durairaj C; Shi H; Wang DD
J Clin Pharmacol; 2020 Feb; 60(2):218-228. PubMed ID: 31489639
[TBL] [Abstract][Full Text] [Related]
9. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
Yamamoto N; Nokihara H; Yamada Y; Goto Y; Tanioka M; Shibata T; Yamada K; Asahina H; Kawata T; Shi X; Tamura T
Cancer Sci; 2012 Mar; 103(3):504-9. PubMed ID: 22145984
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
[TBL] [Abstract][Full Text] [Related]
12. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
14. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
Gao B; Voskoboynik M; Cooper A; Wilkinson K; Hoon S; Hsieh CY; Cai S; Tian YE; Bao J; Ma N; Wang C; Zhang M; Li B; Guo M; Zhou R; Wang X; Xu C; de Souza P
Cancer; 2023 Apr; 129(7):1041-1050. PubMed ID: 36718624
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
[TBL] [Abstract][Full Text] [Related]
18. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
19. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Mehra N; Fizazi K; de Bono JS; Barthélémy P; Dorff T; Stirling A; Machiels JP; Bimbatti D; Kilari D; Dumez H; Buttigliero C; van Oort IM; Castro E; Chen HC; Di Santo N; DeAnnuntis L; Healy CG; Scagliotti GV
Oncologist; 2022 Oct; 27(10):e783-e795. PubMed ID: 36124924
[TBL] [Abstract][Full Text] [Related]
20. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Yonemori K; Shimizu T; Kondo S; Iwasa S; Koyama T; Kitano S; Sato J; Shimomura A; Shibaki R; Suri A; Kase Y; Sumino S; Tamura K; Yamamoto N
Jpn J Clin Oncol; 2021 Apr; 51(5):693-699. PubMed ID: 33621324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
